Targeted delivery of nanoparticles bearing fibroblast growth factor-2 by ultrasonic microbubble destruction for therapeutic arteriogenesis

Small. 2008 Oct;4(10):1769-77. doi: 10.1002/smll.200800806.

Abstract

Therapeutic strategies in which recombinant growth factors are injected to stimulate arteriogenesis in patients suffering from occlusive vascular disease stand to benefit from improved targeting, less invasiveness, better growth-factor stability, and more sustained growth-factor release. A microbubble contrast-agent-based system facilitates nanoparticle deposition in tissues that are targeted by 1-MHz ultrasound. This system can then be used to deliver poly(D,L-lactic-co-glycolic acid) nanoparticles containing fibroblast growth factor-2 to mouse adductor muscles in a model of hind-limb arterial insufficiency. Two weeks after treatment, significant increases in both the caliber and total number of collateral arterioles are observed, indicating that the delivery of nanoparticles bearing fibroblast growth factor-2 by ultrasonic microbubble destruction may represent an effective and minimally invasive strategy for the targeted stimulation of therapeutic arteriogenesis.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Drug Delivery Systems / methods*
  • Fibroblast Growth Factor 2 / administration & dosage*
  • Fibroblast Growth Factor 2 / pharmacology*
  • Glycolates / metabolism
  • Humans
  • Lactic Acid
  • Mice
  • Microbubbles*
  • Models, Biological
  • Muscle, Skeletal / cytology
  • Muscle, Skeletal / drug effects
  • Nanoparticles*
  • Neovascularization, Physiologic / drug effects*
  • Polyglycolic Acid
  • Polylactic Acid-Polyglycolic Acid Copolymer
  • Ultrasonics*

Substances

  • Glycolates
  • Fibroblast Growth Factor 2
  • Polylactic Acid-Polyglycolic Acid Copolymer
  • Polyglycolic Acid
  • Lactic Acid